Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

114
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
114
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

186
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
186
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

122
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
122
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

319
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.

Crohn's & colitis 360·2026
Same author

Resident doctor workforce wellbeing worldwide: lessons between the United Kingdom and Australia.

Clinical medicine (London, England)·2026
Same author

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

The American journal of gastroenterology·2026
Same author

Timing of ileocolic resection for Crohn's disease: A survey of the patient perspective in the 'biological' era.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2026
Same author

Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.

Journal of Crohn's & colitis·2025

Related Experiment Video

Updated: Jun 7, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K

Crohn's disease management: translating STRIDE-II for UK clinical practice.

Karen Kemp1, Mark A Samaan2, Ajay M Verma3

  • 1Department of Gastroenterology, Manchester Clinical Academic Centre, Manchester Royal Infirmary, University of Manchester, Oxford Road, Manchester M13 9WL, UK.

Therapeutic Advances in Gastroenterology
|November 11, 2024
PubMed
Summary

Treat-to-target (T2T) approaches, guided by STRIDE-II, offer improved outcomes for Crohn

Keywords:
Crohn’s diseaseSTRIDE-IIUK clinical practicebest practiceguidelinesinflammatory bowel disease

More Related Videos

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.8K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K

Related Experiment Videos

Last Updated: Jun 7, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.8K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Practice Guidelines

Background:

  • Crohn's disease (CD) management traditionally uses stepwise therapy, but clinical remission poorly correlates with disease activity.
  • Achieving only clinical remission or endoscopic healing may not prevent inflammatory complications in CD patients.
  • Individualized 'treat-to-target' (T2T) strategies show promise for enhancing endoscopic remission and symptom resolution in CD.

Purpose of the Study:

  • To summarize the STRIDE-II guidelines for Crohn's disease (CD) management.
  • To provide guidance for healthcare professionals on applying STRIDE-II principles in UK clinical practice.
  • To offer management recommendations for non-responsive CD patients and suggest endoscopic outcome scoring system utilization.

Main Methods:

  • Review and summarization of the STRIDE-II guidelines.
  • Development of practical recommendations for UK clinicians.
  • Inclusion of management strategies for primary and secondary non-responders.
  • Guidance on using endoscopic outcomes scoring systems.

Main Results:

  • STRIDE-II guidelines provide evidence-based, individualized targets for T2T therapy in IBD.
  • Targets include long-term (quality of life, disability, endoscopic healing) and short-term goals (symptoms, biomarkers).
  • The guidelines facilitate risk-benefit assessment for treatment strategies.

Conclusions:

  • STRIDE-II guidelines offer a framework for personalized T2T management in CD.
  • Application of these guidelines can improve patient outcomes and clinical practice in the UK.
  • Focusing on specific targets beyond simple remission is crucial for effective CD management.